JOP20210250A1 - Capsid assembly modulator solid formulation - Google Patents

Capsid assembly modulator solid formulation

Info

Publication number
JOP20210250A1
JOP20210250A1 JOP/2021/0250A JOP20210250A JOP20210250A1 JO P20210250 A1 JOP20210250 A1 JO P20210250A1 JO P20210250 A JOP20210250 A JO P20210250A JO P20210250 A1 JOP20210250 A1 JO P20210250A1
Authority
JO
Jordan
Prior art keywords
capsid assembly
solid formulation
assembly modulator
modulator
capsid
Prior art date
Application number
JOP/2021/0250A
Other languages
Arabic (ar)
Inventor
Maria Jansens
Jan Snoeys
Oliver Lenz
Michaël Bertil S Anne
Claire Elisabeth Balmain
Abhishek Singh
Dycke Frederic Anne R Van
Joris Jozef Vandenbossche
Dominique Josiane W Verstraete
Original Assignee
Janssen Sciences Ireland Unlimited Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/IB2019/000231 external-priority patent/WO2019175657A1/en
Application filed by Janssen Sciences Ireland Unlimited Co filed Critical Janssen Sciences Ireland Unlimited Co
Publication of JOP20210250A1 publication Critical patent/JOP20210250A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

The present disclosure is directed to solid oral dosage forms of a capsid assembly inhibitor for the treatment of hepatitis B virus infection.
JOP/2021/0250A 2019-03-13 2020-03-13 Capsid assembly modulator solid formulation JOP20210250A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
PCT/IB2019/000231 WO2019175657A1 (en) 2018-03-14 2019-03-13 Capsid assembly modulator dosing regimen
US16/352,754 US10973801B2 (en) 2018-03-14 2019-03-13 Capsid assembly modulator dosing regimen
EP2019056348 2019-03-13
EP19197566 2019-09-16
PCT/EP2020/056991 WO2020183020A1 (en) 2019-03-13 2020-03-13 Capsid assembly modulator solid formulation

Publications (1)

Publication Number Publication Date
JOP20210250A1 true JOP20210250A1 (en) 2023-01-30

Family

ID=72427202

Family Applications (1)

Application Number Title Priority Date Filing Date
JOP/2021/0250A JOP20210250A1 (en) 2019-03-13 2020-03-13 Capsid assembly modulator solid formulation

Country Status (16)

Country Link
EP (1) EP3937928A1 (en)
JP (1) JP2022524819A (en)
KR (1) KR20210137484A (en)
CN (1) CN113557016A (en)
AU (1) AU2020235442A1 (en)
BR (1) BR112021017525A2 (en)
CA (1) CA3132095A1 (en)
CR (1) CR20210481A (en)
EC (1) ECSP21067052A (en)
IL (1) IL286209A (en)
JO (1) JOP20210250A1 (en)
MA (1) MA55280A (en)
MX (1) MX2021011030A (en)
PE (1) PE20212107A1 (en)
SG (1) SG11202109710QA (en)
WO (1) WO2020183020A1 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2017248828A1 (en) 2016-04-15 2018-11-01 Janssen Sciences Ireland Uc Combinations and methods comprising a capsid assembly inhibitor
CN111867582A (en) * 2018-03-14 2020-10-30 爱尔兰詹森科学公司 Capsid assembly modulator dosing regimen

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO3603B1 (en) 2013-05-17 2020-07-05 Janssen Sciences Ireland Uc Sulphamoylpyrrolamide derivatives and the use thereof as medicaments for the treatment of hepatitis b
CN111867582A (en) * 2018-03-14 2020-10-30 爱尔兰詹森科学公司 Capsid assembly modulator dosing regimen

Also Published As

Publication number Publication date
MA55280A (en) 2022-01-19
AU2020235442A1 (en) 2021-08-12
KR20210137484A (en) 2021-11-17
EP3937928A1 (en) 2022-01-19
JP2022524819A (en) 2022-05-10
CR20210481A (en) 2021-10-25
IL286209A (en) 2021-10-31
CN113557016A (en) 2021-10-26
SG11202109710QA (en) 2021-10-28
CA3132095A1 (en) 2020-09-17
PE20212107A1 (en) 2021-11-04
ECSP21067052A (en) 2021-11-18
MX2021011030A (en) 2021-10-13
WO2020183020A1 (en) 2020-09-17
BR112021017525A2 (en) 2021-11-23

Similar Documents

Publication Publication Date Title
PH12020551421A1 (en) Capsid assembly modulator dosing regimen
PH12019500335A1 (en) Therapeutic compounds useful for the prophylactic or therapeutic treatment of an hiv virus infection
MX2020011808A (en) Combinations and methods comprising a capsid assembly inhibitor.
PH12016501631A1 (en) Novel 6-fused heteroaryldihydropyrimidines for the treatment and prophylaxis of hepatitis b virus infection
EA201892034A1 (en) ELIMINATION OF HEPATITIS B VIRUS WITH THE HELP OF ANTI-VIRUS AGENTS
MX2018005230A (en) Combination therapy of an hbv capsid assembly inhibitor and an interferon.
EA201890200A1 (en) DERIVATIVES OF CYCLIZED SULFAMOILARILAMIDE AND THEIR APPLICATION AS A MEDICINE PREPARATION FOR THE TREATMENT OF HEPATITIS B
EA201591220A1 (en) NEW ANTI-VIRAL AGENTS AGAINST HEPATITIS B VIRUS INFECTION
MX2022009352A (en) Nucleotide hemi-sulfate salt for the treatment of hepatitis c virus.
NZ741957A (en) Therapeutic compositions for treatment of human immunodeficiency virus
NZ739248A (en) Inhibitors of hepatitis c virus
MX2021011030A (en) Capsid assembly modulator solid formulation.
MX2019002678A (en) Combined treatment with a tlr7 agonist and an hbv capsid assembly inhibitor.
MX2024006396A (en) Therapeutic compounds for hiv virus infection.
JOP20190214A1 (en) subbstituted Dihydroindene-4-Carboxamides and Analogs Thereof, and Methods Using Same
MX2019009659A (en) Improved dose of baloxavir marboxil for pediatric patients.
EA202192967A1 (en) NEW INDOL-2-CARBOXAMIDES ACTIVE AGAINST HEPATITIS B VIRUS (HBV)
EA202192969A1 (en) NEW OXALILPIPERAZINES ACTIVE AGAINST HEPATITIS B VIRUS (HBV)
EA202191109A1 (en) 5-MEMBER HETEROARYL CARBOXAMIDE COMPOUNDS FOR TREATMENT OF HEPATITIS B VIRUS
MX2021016022A (en) Synergistic effect of eyp001 and ifn for the treatment of hbv infection.
MX2019015236A (en) Use of the rpobenecida and its derivatives as inhibitors of the influenza virus neuraminidase.
CO2022006965A2 (en) egfr inhibitors
EA202092930A1 (en) HEPATITIS B VIRUS CAPSID ASSEMBLY MODULATORS
EA201892348A1 (en) COMBINATIONS AND METHODS INCLUDING THE CAPSIDE ASSEMBLY INHIBITOR
PH12015502258A1 (en) Solid oral dosage formulation of hcv inhibitor in the amorphous state